ASR-2001
Pharmaceutical compound From Wikipedia, the free encyclopedia
ASR-2001, also known as 2CB-5PrO or as 4-bromo-2-methoxy-5-propoxyphenethylamine, is a non-hallucinogenic serotonin receptor agonist agonist of the phenethylamine, 2C, and TWEETIO families which is under development for the treatment of psychiatric disorders.[2][3][4][5][6][7] It is the TWEETIO analogue of 2C-B in which the 5-methoxy group is replaced with a 5-propoxy group.[5][8]
| |
| Clinical data | |
|---|---|
| Other names | ASR2001; 2CB-5PrO; 5-PrO-2C-B; 4-Bromo-2-methoxy-5-propoxyphenethylamine |
| Routes of administration | Oral[1] |
| Drug class | Non-hallucinogenic serotonin 5-HT2A receptor and 5-HT1B receptor agonist |
| ATC code |
|
| Pharmacokinetic data | |
| Onset of action | 1–1.5 hours[1] |
| Duration of action | 8–10 hours[1] |
| Identifiers | |
| |
| PubChem CID | |
| Chemical and physical data | |
| Formula | C12H18BrNO2 |
| Molar mass | 288.185 g·mol−1 |
| 3D model (JSmol) | |
| |
| |
The drug is a non-hallucinogenic serotonin 5-HT2A receptor agonist and is orally active, highly potent, and has high selectivity over the serotonin 5-HT2B receptor (94-fold in terms of activational potency).[3][4][5][1][8] It is also a highly potent agonist of the serotonin 5-HT1B receptor, whereas its activity at the serotonin serotonin 5-HT1A receptor was very weak and its activity at the serotonin 5-HT2C receptor was not described.[8] ASR-2001 showed no significant activity at a variety of other sites, including other serotonin receptors and the monoamine transporters.[8]
According to its developers, ASR-2001 has no overt psychedelic effects, but produces a "focusing-type" "state of mental clarity" without the frank psychostimulant effects of drugs like amphetamine and methylphenidate.[3][4][1] It is said to not disturb but to potentially facilitate detailed work.[1] The drug is said to have a dose range of 10 to 40 mg, an onset of 1 to 1.5 hours, and a duration of 8 to 10 hours.[1] Its effects are described as "subtle".[1]
ASR-2001 is under development by Nicholas V. Cozzi and Paul F. Daley and colleagues at the Alexander Shulgin Research Institute (ASRI).[3][4][1][2] It was first described in 2023[1][3] and was patented in 2024.[5][8] As of early 2025, ASR-2001 is in the preclinical research stage of development.[7][2]
See also
References
External links
Wikiwand - on
Seamless Wikipedia browsing. On steroids.